Abstract
Amitriptyline is one of the leading medications used for migraine as prophylaxis. Amitriptyline may cause various side effects ranging from mild symptoms such as constipation and dry mouth to severe adverse events such as seizures and coma. Here we present a case of a young gentleman who was started on amitriptyline for migraine but developed hypertension. The patient’s blood pressure normalized after stopping amitriptyline but became elevated when reintroduced. The case highlights the possibility of amitriptyline-induced hypertension even without concomitant medication use or high doses. We recommend regular blood pressure monitoring for patients on amitriptyline regardless of the dose.
Keywords: amitriptyline, migraine, side effects, hypertension, high blood pressure, headache, adverse effects, secondary hypertension
Introduction
Migraine headache is a common type of severe headache associated with symptoms like nausea, aura, and photophobia. Migraine headaches were once believed to be due to alteration of cranial blood vessels' tone, which produces different migraine manifestations [1-3]. Most current evidence supports that a primary neuronal dysfunction and the subsequent intra-cranial and extra-cranial changes are behind the migraine's four known phases. The pathophysiology includes cortical spreading depression, trigeminovascular system activation, and increased sensitization of neurons, among other causes [4,5]. Migraine can be classified as episodic (less than 15 days/month) and chronic migraine (more than 15 days/month).
The worldwide prevalence of migraine is around 10%, with higher rates found in North America, South and Central America, Europe, Asia, and Africa, respectively [6]. In comparison, a study in Saudi Arabia showed migraine prevalence as high as 26%, with female predominance [7].
Acute episodic migraines are treated with non-steroidal anti-inflammatory drugs (NSAIDs) and triptans, while several lines of prophylaxis are offered for chronic migraines. Among the first line is amitriptyline, a tricyclic antidepressant (TCA) proven to be a practical choice to prevent migraines but is less favorable for its side effects profile than other drugs [8,9]. Common side effects include but are not limited to tachycardia, increased appetite, weight gain, urinary retention, dry mouth, blurry vision, and constipation [10,11].
Herein, we describe a case of a young gentleman with migraine who received amitriptyline as prophylaxis but developed hypertension and resolved once stopping the drug.
Case presentation
A 26-year-old male, who is medically and surgically healthy, presented with a six-month history of right-sided throbbing headache associated with nausea, vomiting, and photophobia nearly every day. The headache is preceded by 15-30 minutes of blurry vision. Initially, the pain was relieved by lying down in a dark, quiet room or oral acetaminophen. Later, the patient required ibuprofen to alleviate the pain as the headache would persist for two days. Initial examination showed a blood pressure of 123/69 mmHg, a heart rate of 72 beats per minute, and a normal respiratory rate. The neurological examination was completely unremarkable. The basic blood tests were within normal limits.
The patient was diagnosed with migraine headache and started on flunarizine 10 mg once daily. A month later, the patient did not feel any improvement; thus, he has switched to amitriptyline 10 mg once daily. After a month, the dose was increased to 25 mg as there was no improvement. The patient migraine attacks improved to once monthly; however, the patient noticed a new headache character affecting the head's posterior part, not similar to his previous migraine three months after starting amitriptyline. The examination was normal, apart from a blood pressure of 161/82 mmHg. He was asked to monitor his blood pressure at home, which showed an average reading of 160/80 mmHg with few readings reaching 180/90 mmHg. He denied any history of other medications or illicit drug use.
The patient decided to stop amitriptyline and monitor his blood pressure, which normalized after one week. On the next clinic visit, his blood pressure was 111/62 mmHg, and the migraine headache was persistent but responding to analgesics. He was asked to resume amitriptyline to 10 mg and monitor blood pressure, then increase the dose to 25 mg if migraine was not controlled and blood pressure did not increase. After one month, the patient's blood pressure was normal, but he still complains of migraines, so he increased the dose to 25 mg as instructed. However, a week later, the patient's blood pressure readings were high, so the patient stopped amitriptyline. Table 1 shows the patient's blood pressure readings. After six months, the patient was not on any medications, and his blood pressure remained normal. His migraine attacks were much less frequent and responding to simple analgesics.
Table 1. Patient’s blood pressure readings before, during, and after amitriptyline use.
*On amitriptyline 25 mg.
**On amitriptyline 10 mg.
Time | Situation when blood pressure was measured | Blood pressure readings (mmHg) |
Day 1 | First presentation to the clinic | 123/69 |
After 8 weeks | Second visit to the clinic* | 161/82 |
After 8 weeks | Home reading at 9 AM* | 156/77 |
After 8 weeks | Home reading at 9 PM* | 166/84 |
After 9 weeks | Home reading at 9 AM* | 161/89 |
After 9 weeks | Home reading at 9 PM* | 182/99 |
After 11 weeks | Home reading at 9 AM | 119/58 |
After 11 weeks | Home reading at 9 PM | 108/63 |
After 12 weeks | Second visit to the clinic | 111/62 |
After 15 weeks | Home reading at 9 AM** | 113/72 |
After 15 weeks | Home reading at 9 PM** | 99/63 |
After 17 weeks | Home reading at 9 AM* | 143/88 |
After 17 weeks | Home reading at 9 PM* | 149/74 |
After 24 weeks | Third visit to the clinic | 116/65 |
Discussion
Amitriptyline, a well known tricyclic antidepressant, can be used in neurology as a prophylactic treatment to reduce migraine attacks' severity and frequency. In migraine, the required dosages are significantly lower in comparison to therapeutic dosages to treat depression. Neurologists prefer amitriptyline if the patient had concomitant sleep disturbance, depression, and anxiety with migraines [11]. Toxicity is generally not evident if taken alone at lower doses without using other centrally-acting medications like anti-epileptic drugs or serotonergic drugs [12].
In general, amitriptyline side effects include weight gain, generalized weakness and sleepiness, alopecia, blurred vision, dry mouth, vomiting, constipation or diarrhea, urinary retention, and can cause serious side effects like arrhythmia, blood dyscrasias, and hypotension [9-13]. The previously mentioned side effects are caused by the amitriptyline mechanism of action, which are serotoninergic, anticholinergic action, α adrenergic blockade, and nor-epinephrine inhibition reuptake at nerve terminals [12,13].
Hypertension, as a complication, is a rare phenomenon. It has been reported in patients taking amitriptyline in toxic levels with or without other medications [14,15]. In the literature, the use of amitriptyline was reported to cause malignant hypertension, corrected by discontinuing amitriptyline and introducing blood pressure medication urgently [16,17]. It is proposed that blockade of norepinephrine reuptake and increased vascular reactivity can result in increased systemic hypertension. The theory, mentioned earlier, was supported by the evidence that the tricyclic antidepressants worsen blood pressure control in patients with pheochromocytoma [13].
Neurological adverse effects of amitriptyline range from mild to severe and lethal. Usually, the drug intoxication neurologically results in confusion, delirium initially, followed by convulsions and coma [16,17]. Notably, stroke-like presentation and autonomic dysreflexia were reported in a patient with spinal cord injury when on amitriptyline-duloxetine combination therapy [14]. The mechanism by which amitriptyline was thought to cause a similar presentation to stroke was theorized to be related to significant vasoconstriction that can lead to ischemic and subsequent infarction [15,18].
There is an apparent temporal relationship between starting amitriptyline and high blood pressure readings in our patient presentation. Evidence of resolution of hypertension after the second time of discontinuing the medication and long-term monitoring supports the same relationship. It is important to note that this case shows that serious side effects can happen even at a low dose without concomitant use of other medications predisposing to hypertensive crises. Fortunately, the management of our case required only outpatient evaluation with only stopping the medication. Serious side effects and intoxication would require urgent evaluation, which may necessitate critical care interventions from airway protection, support, decontamination, hemodynamic stability, and management of seizures [19,20]. Case prognostication is dependent on different factors, including the dose taken, the level of intoxication, the patient's presentation if the central nervous system is involved or not, and response to treatment as well [18-20].
Conclusions
This case represents the probability of amitriptyline to cause hypertension, even if no other medications were used simultaneously. Regular follow-up for blood pressure, especially on the early days of starting amitriptyline, is considered reasonable, even with small doses. Discontinuing amitriptyline may result in resolving hypertension without the need for antihypertensive medications.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study
References
- 1.Advances in the basic and clinical science of migraine. Charles A. Ann Neurol. 2009;65:491–498. doi: 10.1002/ana.21691. [DOI] [PubMed] [Google Scholar]
- 2.Vasodilation out of the picture as a cause of migraine headache. Charles A. Lancet Neurol. 2013;12:419–420. doi: 10.1016/S1474-4422(13)70051-6. [DOI] [PubMed] [Google Scholar]
- 3.Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Amin F, Asghar M, Hougaard A, et al. Lancet Neurol. 2013;12:454–461. doi: 10.1016/S1474-4422(13)70067-X. [DOI] [PubMed] [Google Scholar]
- 4.Pathophysiology of migraine. Cutrer FM. Semin Neurol. 2006;26:171–180. doi: 10.1055/s-2006-939917. [DOI] [PubMed] [Google Scholar]
- 5.Migraine. Ashina M. N Engl J Med. 2020;383:1866–1876. doi: 10.1056/NEJMra1915327. [DOI] [PubMed] [Google Scholar]
- 6.Role of magnesium in the pathogenesis and treatment of migraine. Sun-Edelstein C, Mauskop A. Expert Rev Neurother. 2009;9:369–379. doi: 10.1586/14737175.9.3.369. [DOI] [PubMed] [Google Scholar]
- 7.Migraine and headache prevalence and associated comorbidities in a large Saudi sample. Muayqil T, Al-Jafen B, Al-Saaran Z, et al. European Neurol. 2018;79:126–134. doi: 10.1159/000487317. [DOI] [PubMed] [Google Scholar]
- 8.Migraine preventative therapy. Silberstein SD, Goadsby PJ. Cephalalgia. 2002;22:491–512. doi: 10.1046/j.1468-2982.2002.00386.x. [DOI] [PubMed] [Google Scholar]
- 9.Analysis of amitriptyline overdose in emergency medicine. Güloglu C, Orak M, Ustündag M, Altunci YA. Emerg Med J. 2011;28:296–299. doi: 10.1136/emj.2009.076596. [DOI] [PubMed] [Google Scholar]
- 10.Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Trindade E, Menon D, Topfer LA, Coloma C. https://www.cmaj.ca/content/cmaj/159/10/1245.full.pdf. CMAJ. 1998;159:1245–1252. [PMC free article] [PubMed] [Google Scholar]
- 11.Unusual complications from amitriptyline intoxication. Nishimura T, Maruguchi H, Nakao A, Nakayama S. BMJ Case Rep. 2017;2017:0. doi: 10.1136/bcr-2017-219257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Taylor & Francis. Philadelphia (PA): Butterworth-Heinemann; 2004. Neurology in Clinical Practice: Principles of Diagnosis and Management. [Google Scholar]
- 13.Malignant hypertension associated with use of amitriptyline hydrochloride. Dunn FG. South Med J. 1982;75:1124–1125. doi: 10.1097/00007611-198209000-00025. [DOI] [PubMed] [Google Scholar]
- 14.Autonomic dysreflexia as a potential adverse effect of duloxetine and amitriptyline combination therapy: a case report. Parke SC, Reyes MR. PM R. 2019;11:214–218. doi: 10.1016/j.pmrj.2018.07.010. [DOI] [PubMed] [Google Scholar]
- 15.Recreational amitriptyline toxicity mimicking basilar artery stroke. Birns J, Henderson K, Bhalla A. Eur J Emerg Med. 2013;20:139–140. doi: 10.1097/MEJ.0b013e3283543c8a. [DOI] [PubMed] [Google Scholar]
- 16.Delayed-onset seizure and cardiac arrest after amitriptyline overdose, treated with intravenous lipid emulsion therapy. Levine M, Brooks DE, Franken A, Graham R. Pediatrics. 2012;130:0–8. doi: 10.1542/peds.2011-2511. [DOI] [PubMed] [Google Scholar]
- 17.Prolonged coma and loss of brainstem reflexes following amitriptyline overdose. Roberge RJ, Krenzelok EP. https://pubmed.ncbi.nlm.nih.gov/11205078/ Vet Hum Toxicol. 2001;43:42–44. [PubMed] [Google Scholar]
- 18.Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient. Pawar PS, Woo DA. Am J Geriatr Pharmacother. 2010;8:595–598. doi: 10.1016/S1543-5946(10)80008-X. [DOI] [PubMed] [Google Scholar]
- 19.Cerebellitis developing after tricyclic antidepressant poisoning. Tatli O, Karaca Y, Gunaydin M, Yurtsever S, Tuten G. Am J Emerg Med. 2013;31:1419–1415. doi: 10.1016/j.ajem.2013.05.001. [DOI] [PubMed] [Google Scholar]
- 20.Guidelines in Emergency Medicine Network (GEMNet): guideline for the management of tricyclic antidepressant overdose. Body R, Bartram T, Azam F, Mackway-Jones K. Emerg Med J. 2011;28:347–368. doi: 10.1136/emj.2010.091553. [DOI] [PubMed] [Google Scholar]